



Insight Pharma Reports Announces Cancer Immunotherapy Report

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies

NEEDHAM, MA, USA, October 2, 2014 /EINPresswire.com/ -- NEEDHAM, MASS. – Cambridge Healthtech Institute's [Insight Pharma Reports](#) announces the Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies report, authored by Allan B. Haberman, Ph.D.

Just published, this report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. It will cover the following principle therapies; checkpoint inhibitors, anticancer vaccines, and adoptive cellular immunotherapy.

Report Highlights Include:

- The September 5, 2014 approval of Merck's PD-1 inhibitor: pembrolizumab (Keytruda), as well as the future outlook of potential combination checkpoint inhibitor therapies
- Most recent info from the 2014 ASCO and AACR meetings
- Survey results from 99 industry experts conducted by Insight Pharma Reports exclusively for this report.
- Exclusive interviews with three high-end professors, researchers and CEOs:
 - o Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center.
 - o Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia).
 - o Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia.

For more information and to purchase this Insight Pharma Report, visit:

www.InsightPharmaReports.com

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology,

business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. www.InsightPharmaReports.com

Kerri Kelley
Insight Pharma Reports
7819721347
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/226867812>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.